Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
Open Access
- 1 September 2020
- journal article
- letter
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (3), 2000673
- https://doi.org/10.1183/13993003.00673-2020
Abstract
Initial combination therapy plays a central role in managing pulmonary arterial hypertension (PAH) [1–4]. Patients with low- or intermediate-risk of 1-year mortality at diagnosis should be treated with initial combination therapy with an endothelin receptor antagonist (ERA) and phosphodiesterase type-5 inhibitor (PDE5i) [2–4]. Benefits of initial therapy with the ERA ambrisentan and PDE5i tadalafil were demonstrated in AMBITION [1]; prospective evidence for other treatment combinations within these drug classes is needed.Funding Information
- Actelion Pharmaceuticals
This publication has 11 references indexed in Scilit:
- Risk stratification and medical therapy of pulmonary arterial hypertensionEuropean Respiratory Journal, 2019
- Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertensionThe Journal of Heart and Lung Transplantation, 2018
- Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertensionJournal of Cardiovascular Medicine, 2018
- Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN TrialAmerican Journal of Cardiovascular Drugs, 2017
- Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertensionEuropean Respiratory Journal, 2017
- Initial dual oral combination therapy in pulmonary arterial hypertensionEuropean Respiratory Journal, 2016
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Respiratory Journal, 2015
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Heart Journal, 2015
- Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2015
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2013